On December 14, 2015, Northwest Biotherapeutics, Inc announced that it responded to shareholder questions about appointments relating to the Company's Board, and an independent investigation of recent allegations in an anonymous internet report and a derivative lawsuit which cites the anonymous internet report. The Company stated that after meetings and deliberations, the Board came to the conclusion that it was not a fit for Elliott Leary to join Company's Board for a number of reasons.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4638 USD | +0.83% | +2.77% | -33.84% |
05-10 | Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-21 | Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors | CI |
1st Jan change | Capi. | |
---|---|---|
-33.84% | 568M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- NWBO Stock
- News Northwest Biotherapeutics, Inc.
- Northwest Biotherapeutics Rejects Board Nomination by Woodford Investment